Trials / Recruiting
RecruitingNCT06883526
Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma
A Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Phase I/II Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
PART 1: 1. To explore the safety of ZG005 in combination with Gecacitinib in patients with relapsed or refractory lymphoma. 2. To determine the recommended Phase II dosing regimen for relapsed or refractory lymphoma. PART 2: To evaluate the efficacy of ZG005 in combination with Gecacitinib in patients with relapsed or refractory lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ZG005 for Injection | intravenous infusion |
| DRUG | Gecacitinib Hydrochloride Tablets | Oral |
Timeline
- Start date
- 2025-05-16
- Primary completion
- 2027-04-01
- Completion
- 2027-05-01
- First posted
- 2025-03-19
- Last updated
- 2026-01-05
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06883526. Inclusion in this directory is not an endorsement.